Introduction: Air pollution has been widely associated with respiratory diseases. Nevertheless, the association between air pollution and exacerbations of bronchiectasis has been less studied. Objective: To analyze the effect of air pollution on exacerbations of bronchiectasis. Methods: This was a retrospective observational study conducted in Badalona. The number of daily hospital admissions and emergency room visits related to exacerbation of bronchiectasis (ICD-9 code 494.1) between 2008 and 2016 was obtained. We used simple Poisson regressions to test the effects of daily mean temperature, SO2, NO2, CO, and PM10 levels on bronchiectasis-related emergencies and hospitalizations on the same day and 1–4 days after. All p values were corrected for multiple comparisons. Results: SO2 was significantly associated with an increase in the number of hospitalizations (lags 0, 1, 2, and 3). None of these associations remained significant after correcting for multiple comparisons. The number of emergency room visits was associated with higher levels of SO2 (lags 0–4). After correcting for multiple comparisons, the association between emergency room visits and SO2 levels was statistically significant for lag 0 (p = 0.043), lag 1 (p = 0.018), and lag 3 (p = 0.050). Conclusions: The number of emergency room visits for exacerbation of bronchiectasis is associated with higher levels of SO2.

Bronchiectasis is a chronic respiratory disease defined by abnormal and permanent dilatation of the bronchi [1]. Many of the patients with bronchiectasis have frequent exacerbations [1], which is associated with a decline in lung function [2] and increased mortality [3, 4].

Variant air pollutants have been described, either gaseous pollutants or particulate matter, and humans enter in contact with these air pollutants primarily via inhalation. The association between air pollution and respiratory diseases is well established [5-11]. Air pollution has been associated with a decrease in lung function [6, 7], exacerbation of preexisting pulmonary diseases [8-10], or even increased mortality [11]. Nevertheless, the association between air pollution and exacerbations of bronchiectasis has been less studied [12-15].

Our objective was to analyze the effect of air pollution on exacerbations of bronchiectasis in Badalona (Barcelona, Spain).

Location

This was an observational, retrospective study, conducted in a hospital in Badalona, a city of the region of Barcelones (Barcelona, Spain). It is located north of Barcelona, on the coast of the Mediterranean Sea. In 2015, the city had 216,085 inhabitants. Hospital Universitari Germans Trias i Pujol is a tertiary hospital with 600 beds. It is also a referral hospital for a population of 700,000. By 2015, there were 28,000 hospital admissions to this institution.

Case Definition

The number of daily hospital admissions and emergency room visits due to exacerbation of bronchiectasis was obtained. We considered exacerbation of bronchiectasis to include all those hospitalizations or emergency department visits with a diagnosis of acute exacerbation of bronchiectasis (International Classification of Diseases [ICD]-9 code 494.1, bronchiectasis with acute exacerbation) in the discharge report, between January 2008 and December 2016. Patients with life-threatening hemoptysis or cystic fibrosis (CF) were excluded, as well as those whose postal code did not correspond to the area of Badalona. To avoid counting the same event twice, emergency room visits followed by an immediate hospitalization were not included in the analysis.

Obtaining Environmental Data

Catalonia has a network of monitoring stations operated by the Department of Environment of the Generalitat de Catalunya. The data were obtained from a station in Badalona (http://dtes.gencat.cat/icqa/, accessed May 13, 2017). The daily average sulfur dioxide (SO2), nitrogen dioxide (NO2), carbon monoxide (CO), and particulate matter with a median aerodynamic diameter of 10 μm or less (PM10) were obtained.

Obtaining Weather Data

Daily mean temperature was obtained from the Catalan Meteorological Agency (http://www.meteo.cat, accessed February 13, 2016) from a station in the center of Badalona. Other weather variables, such as relative humidity, were not available and were not included in the analysis.

Statistical Analysis

We used simple Poisson regressions to test the effects of mean temperature, SO2, NO2, CO, and PM10 levels on bronchiectasis-related emergencies and hospitalizations on the same day and 1–4 days after. To control for multiple comparisons (there were 5 independent variables × 2 events (emergencies and hospitalizations) × 5 time lags = 50 Poisson regressions), we applied a permutation approach. Specifically, the mean temperature and pollutant levels were randomly permuted 5,000 times in time (e.g., simulating that on February 2, 2010, there were the temperature and pollutant levels of April 13, 2014), and the Poisson regressions were repeated using the permuted data. Finally, we created the null distribution of the maximum z value from the maximum z value of each permutation. The effect of seasonality was not assessed.

Ethical Aspects

The study protocol was approved by the Ethics Committee on Clinical Research of the Hospital Universitari Germans Trias and Pujol.

Two-hundred and fifty subjects and 273 exacerbations were included in the study. The characteristics of patients included in the study can be seen in Table 1. The description of temperature and atmospheric pollutants is shown in Table 2. The comparison of the mean levels of temperature and atmospheric pollutants in days with or without exacerbations of bronchiectasis can be seen in Table 3. The evolution of exacerbations and air pollutants according to the month of the year can be seen in Figure 1.

Table 1.

Characteristics of the 250 subjects and 273 exacerbations (128 hospitalizations and 145 emergency room visits) included in the study

Characteristics of the 250 subjects and 273 exacerbations (128 hospitalizations and 145 emergency room visits) included in the study
Characteristics of the 250 subjects and 273 exacerbations (128 hospitalizations and 145 emergency room visits) included in the study
Table 2.

Description of temperature and atmospheric pollutants during the study period (2008–2016)

Description of temperature and atmospheric pollutants during the study period (2008–2016)
Description of temperature and atmospheric pollutants during the study period (2008–2016)
Table 3.

Comparison of mean levels of temperature and atmospheric pollutants in days with or without exacerbations of bronchiectasis

Comparison of mean levels of temperature and atmospheric pollutants in days with or without exacerbations of bronchiectasis
Comparison of mean levels of temperature and atmospheric pollutants in days with or without exacerbations of bronchiectasis
Fig. 1.

Evolution of exacerbations of bronchiectasis and pollutants according to the month of the year. CO, carbon monoxide (μg/m3); ER0, emergency room visits lag 0 (n); H0, hospitalizations lag 0 (n); NO2, nitrogen dioxide (μg/m3); PM10: particulate matter with a median aerodynamic diameter of 10 μm or less (μg/m3); SO2, sulfur dioxide (μg/m3); T, temperature (°C).

Fig. 1.

Evolution of exacerbations of bronchiectasis and pollutants according to the month of the year. CO, carbon monoxide (μg/m3); ER0, emergency room visits lag 0 (n); H0, hospitalizations lag 0 (n); NO2, nitrogen dioxide (μg/m3); PM10: particulate matter with a median aerodynamic diameter of 10 μm or less (μg/m3); SO2, sulfur dioxide (μg/m3); T, temperature (°C).

Close modal

Hospitalizations for Bronchiectasis

The results of Poisson regressions for hospitalizations due to exacerbation of bronchiectasis are exposed in Table 4. SO2 levels were significantly associated with an increase in the number of hospitalizations (lags 0, 1, 2, and 3). None of these associations remained significant after correcting for multiple comparisons.

Table 4.

Results of Poisson regressions for hospitalizations due to exacerbation of bronchiectasis

Results of Poisson regressions for hospitalizations due to exacerbation of bronchiectasis
Results of Poisson regressions for hospitalizations due to exacerbation of bronchiectasis

Emergency Room Visits

The results of Poisson regressions for emergency room visits due to exacerbation of bronchiectasis are shown in Table 5. The number of emergency room visits was associated with higher levels of SO2 (lags 0–4). After correcting for multiple comparisons, the association between emergency room visits and SO2 levels was statistically significant for lag 0 (p = 0.043), lag 1 (p = 0.018), and lag 3 (p = 0.050).

Table 5.

Results of Poisson regressions for emergency room visits due to exacerbation of bronchiectasis

Results of Poisson regressions for emergency room visits due to exacerbation of bronchiectasis
Results of Poisson regressions for emergency room visits due to exacerbation of bronchiectasis

In our study, the number of emergency room visits was associated with higher levels of SO2 (lags 0–4). After correcting for multiple comparisons, the association between emergency room visits and SO2 levels was statistically significant for lags 0, 1, and 3.

Our findings, suggesting an association between air pollution and exacerbation of bronchiectasis, are in line with previous studies which have reported the effect of ambient air pollution in these patients. Goss et al. [12] described an increase in the odds of having two or more exacerbations in CF patients with an increased annual average exposure to several ambient air pollutants, specifically PM10, PM2.5, and ozone. No clear significant association was found with other pollutants (NO2, SO2) in their study, despite the fact that the level of NO2 in their study is similar to ours (24.8 vs. 24) and the level of SO2 is lower in our observation (4.9 vs. 2.6). Another study [13] described a significant increase in the risk of having an exacerbation on days with higher air concentrations of NO2, ozone, and PM10. Nevertheless, in this study, the authors did not investigate the effect of SO2 on CF exacerbations. Goeminne et al. [14] found that living near a major road was associated with an increased mortality in patients with non-CF bronchiectasis, describing for the first time the impact of traffic-related pollution on patients with non-CF bronchiectasis. More recently, Garcia-Olivé et al. [15] described an increase in hospital admissions for exacerbation of bronchiectasis in those months with higher atmospheric concentrations of SO2 and lower mean temperature.

SO2 is a gas that is rapidly oxidized to sulfuric acid in contact with epithelial surfaces in the nasopharynx and lower airways, where it may cause damage [16]. It is a major airborne pollutant in industrialized countries, and the primary outdoor source of SO2 is the combustion of sulfur-containing fossil fuels (coal and oil). SO2 exposure has been associated with chronic cough, sputum production [17, 18], bronchoconstriction [19, 20], or irreversible airway obstruction [21] and one study even described the case of a patient who developed severe bronchiectasis after acute sulfur dioxide poisoning [22].

The mechanisms by which SO2 can damage the lungs have been well studied [23-27]. In chronically exposed animals, it has been seen to cause mucus gland hypersecretion and replacement of ciliated cells by nonciliated cells [23]. Several authors have described dysfunction of mucociliary clearance in animals exposed to SO2 [24-26]. This functional impairment can be reversible [24] and might occur at concentrations which yield no detectable morphological alterations, such as widening of intercellular spaces [25]. When the barrier function of the airway mucosa and/or the mucociliary function are impaired, the contact of bacteria with the mucosa could be increased and the invasion of inhaled pathogens could be eased [25], thus predisposing to exacerbations. In a study analyzing the bronchoalveolar fluid of 12 subjects exposed to SO2, the authors found and increase in lysozyme-positive alveolar macrophages and mild lymphocytosis [16]. Seventy-two hours after exposure, total cell numbers had virtually returned to pre-exposure levels. On the contrary, Li et al. [27] did not found any obvious inflammatory response in rat lungs exposed to SO2. Given the fact that the key components of the disease are chronic bronchial infection, inflammation, impaired mucociliary clearance, and structural lung damage [1], air pollution could play a role in exacerbations in patients without clear signs of bronchial infection.

Our study has several limitations. First, it is a retrospective study. Secondly, the definition of exacerbation is based on diagnostic codification at the time of discharge; therefore, we cannot exclude the possibility of errors in codification. Third, we considered the first day of the exacerbation to be the day the patient is admitted to the hospital, while certainly the symptoms had begun earlier. And last, although we have not included those patients with a postal code that does not belong to our city, the real time of exposure remains uncertain. Strengths of this paper are its long follow-up period and the fact that we have included ambient temperature in the analysis, which could have acted as a confounder.

In short, we have detected an increase in the number of emergency room visits for exacerbation of bronchiectasis associated with higher levels of SO2, especially on the same day (lag 0) and the day after (lag 1). Further studies with different geographical locations and larger follow-up improving the exposure assignment are desirable in order to improve our understanding of the effects of ambient air pollution on patients with bronchiectasis.

The authors do not have any financial or personal relationships with people or organizations that could inappropriately influence their work in the present article.

Study design: I.G.-O., Z.S. Data collection: I.G.-O., Z.S., L.R.-P., C.M.-R. Statistical analysis: J.R. Writing of the manuscript: I.G.-O., Z.S. Critical reading of the manuscript: I.G.-O., Z.S., J.R., L.R.-P., C.M.-R., J.R.M.

1.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD: European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629.
2.
Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J: Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565–1572.
3.
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT: The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576–585.
4.
Martinez-Garcia MA, Athanazio RA, Girón R, Máiz-Carro L, de la Rosa D, Olveira C, de Gracia J, Vendrell M, Prados-Sánchez C, Gramblicka G, Corso Pereira M, Lundgren FL, Fernandes De Figueiredo M, Arancibia F, Rached SZ: Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis 2017; 12: 275–284.
5.
Brunekreef B, Holgate ST: Air pollution and health. Lancet 2002; 360: 1233–1242.
6.
Rice MB, Ljungman PL, Wilker EH, Gold DR, Schwartz JD, Koutrakis P, Washko GR, O’Connor GT, Mittleman MA: Short-term exposure to air pollution and lung function in the Framingham Heart Study. Am J Respir Crit Care 2013; 188: 1351–1357.
7.
Lepeule J, Litonjua AA, Coull B, Koutrakis P, Sparrow D, Vokonas PS, Schwartz J: Longterm effects of traffic particles on lung function decline in the elderly. Am J Respir Crit Care Med 2014; 190: 542–548.
8.
Hansel NN, McCormack MC, Kim V: The effects of air pollution and temperature on COPD. COPD 2016; 13: 372–379.
9.
Garcia-Olivé I, Radua J, Fiz JA, Sanz-Santos J, Ruiz-Manzano J: Association between air pollution and hemoptysis. Can Respir J 2016; 2016: 9242185.
10.
Johannson KA, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J 2014; 43: 1124–1131.
11.
DeVries R, Kriebel D, Sama S: Outdoor air pollution and COPD-related emergency department visits, hospital admissions, and mortality: a meta-analysis. COPD 2017; 14: 113–121.
12.
Goss CH, Newsom SA, Scjildcrout JS, Sheppard L, Kaufman JD: Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care 2004; 169: 816–821.
13.
Goeminne PC, Kicinski M, Vermeulen F, Fie­rens F, De Boeck K, Nemery B, Nawrot TS, Dupont LJ: Impact of air pollution on cystic fibrosis pulmonary exacerbations. A case-crossover analysis. Chest 2013; 143: 946–954.
14.
Goeminne PC, Bijnens E, Nemery B, Nawrot TS, Dupont LJ: Impact of traffic related air pollution indicators on non-cystic fibrosis bronchiectasis mortality: a cohort analysis. Respir Res 2014; 15: 108.
15.
Garcia-Olivé I, Radua J, Sánchez-Berenguer D, Hernández-Biette A, Raya-Márquez P, Stojanovic Z, Martínez-Rivera C, Fernandez Serrano S, Ruiz Manzano J: Association between environmental factors and hospitalisations for bronchiectasis in Badalona, Barcelona, Spain (2007–2015). Med Clin (Barc) 2017, in press.
16.
Sandström T, Stjernberg N, Andersson M-C, Kolmodin-Hedman B, Lundgren R, Angström T: Is the short term limit value for sulphur dioxide exposure safe? Effects of controlled chamber exposure investigated with bronchoalveolar lavage. Br J Ind Med 1989; 46: 200–203.
17.
Iwisawa S, Kikuchi Y, Nishiwaki Y, Nakano M, Michikawa T, Tsuboi T, Tanaka S, Uemura T, Ishigami A, Nakashima H, Takebayashi T, Adachi M, Mirikawa A, Maruyama K, Kudo S, Uchiyama I, Omae K: Effects of SO2 on respiratory system of adult Miyakejima resident 2 years after returning to the island. J Occup Health 2009; 51: 38–47.
18.
Nieminen P, Panychev D, Lyalyushkin S, Komarov G, Nikanov A, Borisenko M, Kinnula VL, Toljamo T: Environmental exposure as an independent risk factor of chronic bronchitis in northwest Russia. Int J Circumpolar Health 2013; 72: 19742.
19.
Nadel JA, Salem H, Tamplin B, Tokiwa Y: Mechanism of bronchoconstriction during inhalation of sulfur dioxide. J Appl Physiol 1965; 20: 164–167.
20.
Horstman DH, Seal E Jr, Folinsbee LJ, Ives P, Roger LJ: The relationship between exposure duration and sulfur dioxide-induced bronchoconstriction in asthmatic subjects. Am Ind Hyg Assoc J 1988; 49: 38–47.
21.
Charan NB, Myers CG, Lakshminarayan S, Spencer TM: Pulmonary injuries associated with acute sulfur dioxide inhalation. Am Rev Resp Dis1979; 119: 555–560.
22.
Smith FJ, Needles RJ: Bronchiectasis, a late effect of acute sulphur dioxide poisoning, with report of a case. Trans Am Clin Climatol Assoc 1937; 53: 109–116.
23.
Lamb D, Reid L: Mitotic rates, goblet cell increase and histochemical changes in mucus in rat bronchial epithelium during exposure to sulphur dioxide. J Pathol Bacteriol 1968; 96: 97–111.
24.
Man SFP, Hulbert WC, Man G, Mok K, Williams DJ: Effects of SO2 exposure on canine pulmonary epithelial functions. Exp Lung Res 1989; 15: 181–198.
25.
Riechelmann H, Maurer J, Kienast K, Hafner B, Mann WJ: Respiratory epithelium exposed to sulfur dioxide – functional and ultrastructural alterations. Laryngoscope 1995; 105: 295–299.
26.
Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M: Regulation of mucociliary clearance in health and disease. Eur Respir J 1999; 13: 1177–1188.
27.
Li R, Zhao L, Tong J, Yan Y, Xu C: Fine particulate matter and sulfur dioxide coexposures induce rat lung pathological injury and inflammatory responses via TLR4/p38/NF-kB pathway. Int J Toxicol 2017; 36: 165–173.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.